Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Autor: Yiu, Zenas Z.N., Smith, Catherine H., Ashcroft, Darren M., Lunt, Mark, Walton, Shernaz, Murphy, Ruth, Reynolds, Nick J., Ormerod, Anthony D., Griffiths, Christopher E.M., Warren, Richard B.

Publikováno v: In Journal of Investigative Dermatology March 2018 138(3):534-541

Comparison of the two most commonly used treatments for pyoderma gangrenosum : results of the STOP GAP randomised controlled trial

Autor: UK Dermatology Clinical Trials Network’s STOP GAP team, Ormerod, Anthony D, Thomas, Kim S, Craig, Fiona E, Mitchell, Eleanor, Greenlaw, Nicola, Norrie, John, Mason, James M, Walton, Shernaz, Johnston, Graham A, Williams, Hywel C

Publikováno v: BMJ: British Medical Journal, 2015 Jun 01. 350

Externí odkaz: https://www.jstor.org/stable/26520880

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma.

Autor: Khanolkar, Rahul C., Zhang, Chu, Al-Fatyan, Farah, Lawson, Linda, Depasquale, Ivan, Meredith, Fiona M., Muller, Frank, Nicolson, Marianne, Dahal, Lekh Nath, Abu-Eid, Rasha, Rajpara, Sanjay, Barker, Robert Norman, Ormerod, Anthony D., Ward, Frank James

Publikováno v: Frontiers in Immunology; 1/5/2022, Vol. 12, p1-14, 14p

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the UK and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Autor: Yiu, Z. Z. N., Ashcroft, D. M., Evans, I, McElhone, K., Lunt, M., Smith, C. H., Walton, S., Murphy, R., Reynolds, N. J., Ormerod, A. D., Griffiths, C. E. M., Warren, R. B., Irshad, Shamila, Wilde, Victoria, Tahir, Saliha, Ali, Hassan, Mason, Kayleigh, Hussain, Sagair, Granger, Emily, Chalmers, Robert, Flohr, Carsten, Watson, Karen, Prieto-Merino, David, Barker, Jonathan, Benham, Marilyn, Burden, David, Griffiths, Christopher, Kirby, Brian, Lawson, Linda, Ormerod, Anthony, Owen, Caroline, Reynolds, Nick, Warren, Richard

Publikováno v: Yiu, Z Z N, Ashcroft, D M, Evans, I, McElhone, K, Lunt, M, Smith, C H, Walton, S, Murphy, R, Reynolds, N J, Ormerod, A D, Griffiths, C E M, Warren, R B, Irshad, S, Wilde, V, Tahir, S, Ali, H, Mason, K, Hussain, S, Granger, E, Chalmers, R, Flohr, C, Watson, K, Prieto-Merino, D, Barker, J, Benham, M, Burden, D, Griffiths, C, Kirby, B, Lawson, L, Ormerod, A, Owen, C, Reynolds, N, Smith, C H & Warren, R 2019, ' Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the UK and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR) ', British Journal of Dermatology, vol. 180, no. 2, pp. 329-337 . https://doi.org/10.1111/bjd.17036

BackgroundPatients with psoriasis and clinicians are concerned that infliximab may be associated with a risk of serious infections.ObjectivesTo compare the risk of serious infections associated with infliximab in patients with chronic plaque psoriasi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2761::50c4559e45eb718290e28385f0776943
https://kclpure.kcl.ac.uk/en/publications/bc944fb7-066c-46c4-9107-b0e81596c22e